drugset / Trial / NCT05666687

An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain

NCT05666687

Phase 1 Completed 10 enrolled Novartis Pharmaceuticals
Non-randomizedSequentialOpen-labelBasic science

Summary

The purpose of this study is to confirm binding of MIJ821 to the NR2B-containing NMDA receptors in the human brain and assess the PC-RO relationship over time using positron emission tomography (PET).

Timeline

Start
2023-01-11
Primary completion
2023-11-07
Completion
2023-11-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Onfasprodil Small molecule Intravenous